About precipio - PRPO
Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. It operates through the following business divisions: Pathology Services and Products. The Pathology Services division provides specialized cancer diagnostic testing services to physicians, hospitals, and laboratories. The Products divisions develops and commercializes proprietary assays designed for use by clinical laboratories. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.
PRPO At a Glance
Precipio, Inc.
4 Science Park
New Haven, Connecticut 06511
| Phone | 1-203-787-7888 | Revenue | 24.05M | |
| Industry | Medical/Nursing Services | Net Income | -363,000.00 | |
| Sector | Health Services | 2025 Sales Growth | 29.77% | |
| Fiscal Year-end | 12 / 2026 | Employees | 61 | |
| View SEC Filings |
PRPO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.534 |
| Price to Book Ratio | 2.811 |
| Price to Cash Flow Ratio | 53.85 |
| Enterprise Value to EBITDA | 68.885 |
| Enterprise Value to Sales | 1.575 |
| Total Debt to Enterprise Value | 0.096 |
PRPO Efficiency
| Revenue/Employee | 394,245.902 |
| Income Per Employee | -5,950.82 |
| Receivables Turnover | 12.121 |
| Total Asset Turnover | 1.255 |
PRPO Liquidity
| Current Ratio | 1.61 |
| Quick Ratio | 1.36 |
| Cash Ratio | 0.707 |
PRPO Profitability
| Gross Margin | 37.232 |
| Operating Margin | -4.998 |
| Pretax Margin | -1.509 |
| Net Margin | -1.509 |
| Return on Assets | -1.895 |
| Return on Equity | -2.724 |
| Return on Total Capital | -1.993 |
| Return on Invested Capital | -2.397 |
PRPO Capital Structure
| Total Debt to Total Equity | 25.088 |
| Total Debt to Total Capital | 20.056 |
| Total Debt to Total Assets | 17.137 |
| Long-Term Debt to Equity | 20.63 |
| Long-Term Debt to Total Capital | 16.493 |